Comments
Loading...

Arcturus Therapeutics

ARCTNASDAQ
Logo brought to you by Benzinga Data
$21.50
0.954.62%
Last update: 11:03 AM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$86.00
Lowest Price Target1
$14.00
Consensus Price Target1
$50.18

Arcturus Therapeutics (NASDAQ:ARCT) Stock, Analyst Ratings, Price Targets, Forecasts

Arcturus Therapeutics Holdings Inc has a consensus price target of $50.18 based on the ratings of 15 analysts. The high is $86 issued by Canaccord Genuity on May 10, 2024. The low is $14 issued by Goldman Sachs on November 10, 2022. The 3 most-recent analyst ratings were released by Leerink Partners, HC Wainwright & Co., and HC Wainwright & Co. on August 12, 2024, August 8, 2024, and July 2, 2024, respectively. With an average price target of $64.33 between Leerink Partners, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 199.22% upside for Arcturus Therapeutics Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
May
0
0
0
0
Jul
2
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Leerink Partners
HC Wainwright & Co.
Canaccord Genuity
HC Wainwright & Co.
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Arcturus Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Arcturus Therapeutics (ARCT) stock?

A

The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting ARCT to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arcturus Therapeutics (ARCT)?

A

The latest analyst rating for Arcturus Therapeutics (NASDAQ:ARCT) was provided by Cantor Fitzgerald, and Arcturus Therapeutics reiterated their overweight rating.

Q

When was the last upgrade for Arcturus Therapeutics (ARCT)?

A

The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.

Q

When was the last downgrade for Arcturus Therapeutics (ARCT)?

A

The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for Arcturus Therapeutics (ARCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

Q

Is the Analyst Rating Arcturus Therapeutics (ARCT) correct?

A

While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Arcturus Therapeutics (ARCT) is trading at is $21.50, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch